Ceralasertib

• RESTORING SENSITIVITY TO IMMUNOTHERAPY IN ADVANCED TRIPLE NEGATIVE BREAST CANCER EXPLOITING CERALASERTIB PRIMING FOLLOWED BY COMBINED DURVAL… Ended
  2024-513721-23-00 Phase II 1 country IFOM Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets
• Study of ceralasertib plus durvalumab versus docetaxel for patients with advanced or metastatic non-small cell lung cancer Ended
  2023-509429-37-00 Phase III 10 countries AstraZeneca AB
• A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanc… Ended
  2024-512378-91-00 Phase II 6 countries AstraZeneca AB
• Phase II umbrella study of novel anti-cancer agents in patients with NSCLC who progressed on an anti-PD-1/PD-L1 containing therapy. Ended
  2023-509004-15-00 Phase II/III 4 countries AstraZeneca AB
• A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combinatio… Ended
  2024-514205-60-00 Phase II 3 countries AstraZeneca AB
• A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer Ended
  2024-515102-12-00 Phase II 1 country AstraZeneca AB
• Precision Immuno-Oncology for advanced Non-small cell lung cancer patients with PD-1 ICI Resistance (PIONeeR clinical study) Ended
  2024-515532-72-00 Phase II 1 country Centre Hospitalier Regional De Marseille
• AUSTRAL trial: An open-label, multicenter, phase II study of radiotherapy followed by durvalumab (MEDI4736) and ceralasertib (AZD6738) in st… Ended
  2024-515942-18-01 Phase II 1 country Istituto Di Ricerche Farmacologiche Mario Negri

Showing 1–8 of 8 trials